ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0306

Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy

Akanksha Sharma1, shiri keret2, Raisa Lomanto Silva3, Tanya Chandra4, Joel Levin5, Siamak Moghadam-Kia3, Chester V. Oddis6 and Rohit Aggarwal6, 1UPMC Mercy Hospital, Pittsburgh, PA, 2Bnai Zion, Atlit, Israel, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Georgetown University Hospital, Washington, DC, 5University of Pittsburgh, Katz Graduate School, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, Disease Activity, Myositis, pain, physical function

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Idiopathic inflammatory myopathies (IIM, myositis) are a systemic autoimmune disease leading to debilitating muscle weakness and significant limitations in daily activities. Physical activity monitor (PAM) are validated and recognized measures of the frequency and intensity of physical activities. Given the urgent need for objective, continuous, longitudinal outcome measures of physical activity and function in myositis, we assessed compliance, reliability, and validity of widely used commercial PAM – Fitbit© in evaluating physical activity in myositis patients.

Methods: “Myositis Patient Centered Tele-Research (MyPACER)” is a multi-center observational prospective study conducted over 6 months. The study had two cohorts, 1. Tele-Research Cohort (TRC): patients were remotely enrolled from any location in the United States, and 2. Center-Based Cohort (CBC): a traditional cohort with enrollment from the 2 myositis centers. Functional and Patient-Reported Assessments were completed monthly, including a health assessment questionnaire, patient global disease activity, PROMIS-physical function 20 and functional tests timed up-and-go (TUG), and sit-to-stand (STS)). Participants were asked to use their waist-based Fitbit (≥10 hours/day), ≥ 7 days/month. Average steps per minute & Average peak cadence were evaluated using Fitbit data.

Results: 120 IIM patients (mean age 55.5+/- 13.43, 75% females, 80.8% white), who completed baseline visit were enrolled in the study, comprising 82 in the Main TRC group, 21 in Local TRC and 17 in the local CBC (table 1). There were 51.7% DM, 39.2% PM, and 9.1% NM. The TRC and CBC cohorts were similar in demographics and disease subtypes. Age was significantly correlated with the average steps per minute (Ave Step/min) (p=0.01) but not with ave. peak cadence, showing a decrease in steps with advancing age. Gender, race/ethnicity or disease subtypes were not associated with PAM measures.

On data analysis, 90% patients completed at least one valid day on their Fitbit devices. The compliance with Fitbit was very high with participants wearing devices on most days of the week (Ave. = 6.52 days) for the most visits (Ave. 5.73 visits), with similar results for remote or local recruitment. Ave steps per minute and peak cadence showed strong test-retest reliability (r=0.89 and r=0.86, p< 0.0001 & p= 0.0001) and were strongly correlated within-patient. Regarding validity at baseline, ave steps/mins was significantly associated with myositis, skin disease, extra-muscular global, PROMIS physical function and functional tests, HAQ score but not with other myositis core set measures (Table 2).While the ave. peak cadence was significantly associated with MMT-8, physician and patient global disease activity as well as fatigue, myalgia, myositis, TUG, but not with HAQ, CK, and extra-muscular disease activity (Table 2).

Conclusion: In a large IIM cohort, Fitbit physical activity monitor variables demonstrates favorable compliance and psychometric properties with a strong test-retest reliability and association of several patient and physician-reported measures.

Supporting image 1

Table 1. Demographic characteristics of participants

Supporting image 2

Table 2: Cross-sectional association of Fitbit measures (average daily steps per minute, and average peak cadence) with various myositis outcome measures at baseline.


Disclosures: A. Sharma: None; s. keret: None; R. Lomanto Silva: None; T. Chandra: None; J. Levin: None; S. Moghadam-Kia: None; C. V. Oddis: Boehringer-Ingelheim, 5, Cabaletta, 5, EMD Serono, 5, Novartis, 5, Pfizer, 1; R. Aggarwal: Actigraph, 2, Alexion, 2, ANI Pharmaceuticals, 2, Argenx, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, CabalettaBio, 2, Capella Bioscience, 2, Corbus, 2, CSL Behring, 2, EMD Serono, 2, 5, Galapagos, 2, Horizon Therapeutics, 2, I-Cell, 2, Janssen, 2, 5, Kezar, 2, Kyverna, 2, Mallinckrodt, 5, Merck, 2, Octapharma, 2, Pfizer, 2, 5, Q32, 5, Roivant, 2, Sanofi, 2, Teva, 2.

To cite this abstract in AMA style:

Sharma A, keret s, Lomanto Silva R, Chandra T, Levin J, Moghadam-Kia S, V. Oddis C, Aggarwal R. Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/fitbit-is-a-valid-and-reliable-physical-activity-monitor-in-idiopathic-inflammatory-myopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fitbit-is-a-valid-and-reliable-physical-activity-monitor-in-idiopathic-inflammatory-myopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology